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The aim of this study was to assess the diversity and genomic variability of Pseudomonas aeruginosa isolates
from cystic fibrosis (CF) patients being treated at a university hospital in Brazil. Ninety-seven isolates of P.
aeruginosa from 43 CF patients were characterized by macrorestriction analysis of chromosomal DNA by
pulsed-field gel electrophoresis (PFGE) and tested for susceptibility to 20 antimicrobial agents by broth
microdilution. It was possible to evaluate single isolates from 20 patients and multiple isolates (two to seven)
from 23 patients collected during a 22-month period. Among all of the unrelated patients, we detected only one
pair of patients sharing a common strain. Among the 77 isolates from 23 patients who had multiple isolates
analyzed, we identified 37 major types by PFGE, and five different colonization patterns were recognized. The
isolates were susceptible to several antimicrobial agents, although consecutive isolates from the same patient
may display differences in their susceptibilities. Mucoid isolates were more resistant (P < 0.001) than
nonmucoid isolates to five antibiotics. Our results indicate that CF patients remain colonized by more than one
strain of P. aeruginosa for long periods of time. In addition, the finding of several different genotypes in the
same patient suggests that the colonizing strain may occasionally be replaced.
When cystic fibrosis (CF) was first described in 1938, 80% of
affected babies died within the first year of life (2). The better
understanding of the disease and the improvements in treat-
ment conditions in recent years have resulted in a dramatic
increase in the median survival time for patients with CF (7).
Nowadays, most patients reach adulthood, but Pseudomonas
aeruginosa continues to be the most prevalent cause of infec-
tions in these patients. This pathogen is one of the main causes
of morbidity and mortality in CF patients (3, 8, 9, 11, 13).
It is generally accepted that once colonized with P. aerugi-
nosa, most patients tend to harbor a conserved type (or clone)
during the course of the disease (5, 21, 26, 28, 29, 30). Patients
may also harbor variants of the original clone, which are char-
acterized by minor differences in genome fingerprints. Con-
versely, Boukadida et al. (4) found distinct strains within the
same patient, indicating that there may be a relatively high
heterogeneity of strains of P. aeruginosa in the pulmonary
microbiota of chronically infected CF patients. Those authors
also found that the emergence of distinct strains in the same
CF patient was often associated with previous courses of an-
tibiotic therapy. It therefore appears that the epidemiology of
P. aeruginosa in CF patients may vary in different medical
centers.
Hospital de Clı´nicas de Porto Alegre (HCPA) is a 700-bed
university hospital located in southern Brazil. HCPA includes
a center for treatment of individuals with CF where more than
150 patients have been monitored. The present study aimed to
characterize isolates of P. aeruginosa from CF patients being
treated at HCPA according to their susceptibility to antimicro-
bial agents and their DNA macrorestriction profiles.
MATERIALS AND METHODS
Bacterial isolates. We collected P. aeruginosa isolates from 43 CF patients
attending the CF center of HCPA from March 1996 to December 1997. The
clinical specimens were processed for qualitative aerobic culture according
to conventional diagnostic methods (18). The identification of isolates was
performed with the Vitek systems (BioMerieux, Hazelwood, Mo.) using the
GNI card. All isolates were subcultured on nutrient agar slants and stored at
room temperature before complementary tests (antibiogram and molecular
typing).
Antibiogram. The antimicrobial susceptibilities of isolates to 20 compounds
were evaluated by broth microdilution using MicroScan Dried Gram Negative
MIC/Combo panels according to NCCLS instructions (19). A standard suspen-
sion of the organism was used to inoculate the panels, which were incubated at
35°C for a minimum of 16 h. The MIC was determined as the lowest antimicro-
bial concentration showing inhibition of growth. The following antimicrobial
agents were tested: cefoxitin, ceftizoxime, ceftazidime, cefotaxime, ceftriaxone,
cefoperazone, cefpodoxime, cefepime, imipenem, meropenem, ampicillin-sul-
bactam, ciprofloxacin, aztreonam, amoxicillin-clavulanate, ticarcillin-clavulanate,
mezlocillin, sparfloxacin, piperacillin-tazobactam, netilmicin, and azlocillin.
P. aeruginosa ATCC 27853 was used as the quality control strain. The results
were interpreted according to the NCCLS criteria (20).
Seven of the 20 antimicrobial agents tested were chosen to establish the
antibiotype of each isolate: ceftazidime, cefepime, imipenem, ciprofloxacin, netil-
micin, aztreonam, and piperacilin-tazobactam. These compounds were selected
because they represent the different classes of antimicrobial agents and because
they are commonly used for the treatment of P. aeruginosa infections. Differences
between the results from susceptible to resistant and from resistant to susceptible
with at least one of these seven antimicrobial agents characterized a different
antibiotype, which was represented by a capital letter. Differences in the results
from susceptible to intermediate or from intermediate to susceptible character-
ized a variation of that antibiotype (subtype), and an arabic number was added
to the capital letter. The MIC at which 50% of the isolates tested are inhibited
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(MIC50), MIC90, and percent susceptibility for these compounds were also cal-
culated.
The isolates were classified according to their colonial morphology on blood
agar as mucoid or nonmucoid, and the rates of susceptibility to each antimi-
crobial agent of these two groups were compared using the Fisher exact test
(10).
Molecular typing. All isolates were characterized by macrorestriction analysis
of chromosomal DNA by pulsed-field gel electrophoresis (PFGE) (24). Genomic
DNA inserts were digested at 37°C overnight (12 to 16 h) with 10 U of SpeI
enzyme (New England Biolabs, Inc., Beverly, Mass.). Electrophoresis was per-
formed in a CHEF-DRII apparatus (Bio-Rad, Richmond, Calif.) with the fol-
lowing conditions: 0.5 Tris-borate-EDTA, 1% agarose, 13°C, and 200 V. The
electrophoresis was run for 24 h, and the switch interval was ramped from 5 to
90 s (24). Photographs of ethidium bromide-stained gels were examined visually.
Isolates were considered distinct strains if there were more than six fragment
(band) differences between PFGE profiles. Isolates were considered related
(subtypes) if there were only two to six band differences between PFGE
profiles. Isolates with the same PFGE profile were considered indistinguish-
able (31).
RESULTS
A total of 97 clinical isolates of P. aeruginosa from 43 CF
sputum samples were obtained between March 1996 and De-
cember 1997. The carbapenens meropenem (96.9% suscepti-
bility; MIC90, 2 g/ml) and imipenem (93.8% susceptibility;
MIC90, 4 g/ml) were the most active compounds against the
P. aeruginosa isolates evaluated in this study. Piperacillin-ta-
zobactam (85.6% susceptibility), ticarcillin-clavulanate (83.5%
susceptibility), and ceftazidime (81.4% susceptibility) also dis-
played reasonable in vitro antimicrobial activity. The results of
MIC50, MIC90, and susceptibility rate determinations were
classified according to colonial morphology (mucoid and non-
mucoid) of the isolates (Table 1). The nonmucoid isolates were
significantly more susceptible (P  0.001) to cefoperazone,
cefepime, ciprofloxacin, aztreonam, and sparfloxacin (Table 1).
The nonmucoid isolates also displayed higher rates of suscep-
tibility than the mucoid isolates to ceftazidime, imipenem,
ticarcillin-clavulanate, piperacillin-tazobactam, and meropen-
em, but with no statistical significance.
The isolates were separated into two different groups: group
1, which was composed of 20 isolates from 20 patients, and
group 2, which included 77 isolates from 23 patients (two to
seven isolates from each patient). A total of 19 distinct strains
(major PFGE profiles) were observed in group 1 isolates.
Only two unrelated patients were colonized with indistin-
guishable strains of P. aeruginosa in this group (Fig. 1). On
the other hand, it was possible to identify 37 major PFGE
profiles among the isolates of group 2, indicating a consid-
erable genomic diversity of P. aeruginosa from different pa-
tients (Fig. 2). Two patients (siblings) of group 2 shared in-
distinguishable strains of P. aeruginosa. In total, 13 isolates
of these two patients were typed, and 12 of them displayed
the same PFGE pattern.
It was possible to obtain multiple isolates from the 23 pa-
tients of group 2 over a period of time of up to 17 months.
Thirteen patients (56%) harbored at least two distinct strains
over their follow-up period, although most of these patients
tended to harbor a single strain (genotype) over many months
(persistence of genotype) (Table 2). P. aeruginosa of anti-
biotype A (susceptible to ceftazidime, ticarcillin-clavulanate,
piperacillin-tazobactam, imipenem, and meropenem) or its
subtypes was seen in 14 patients, but no association between
genotype and antibiotype was observed, as isolates of the same
genotype displayed different antibiotypes and vice versa (Table
2).
We identified 18 patients harboring the same strain over
different periods of time, and 12 of them were colonized with
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Ceftizoximec 8 16–32 64 32 32 7.5 32 32 5.3 0.65
Ceftazidime 8 16 32 4 32 70.0 2 16 89.5 0.096
Cefotaximec 8 16–32 64 32 64 25.0 32 64 14.0 0.173
Ceftriaxonec 8 16–32 64 32 64 27.5 64 64 21.0 0.464
Cefoperazon 16 32 64 16 32 57.5 3 32 79.0 0.00086d
Cefepime 8 16 32 16 16 42.5 4 16 83.0 0.000047d
Imipenem 4 8 16 1 4 90.0 1 2 96.5 0.19
Ampicillin-sulbactamc 8–4 16–8 32–16 32–16 32–16 5.0 32–16 32–16 1.7 0.365
Ciprofloxacin 1 2 4 1 4 50.0 0.25 2 86.0 0.00012d
Aztreonam 8 16 32 8 32 50.0 4 32 84.0 0.00031d
Amoxicillin-clavulanatec 8–4 16–8 32–16 32–16 32–16 2.5 32–16 32–16 1.7 0.800
Ticarcillin-clavulanate 64–2 128–2 16 128 87.5 16 128 80.7 0.376
Mezlocillin 64 128 64 128 52.5 32 128 70.2 0.077
Sparfloxacin 1 2 4 2 2 30.0 1 2 68.4 0.00020d
Piperacillin-tazobactam 64–4 128–4 8 64 80.0 8 64 89.5 0.19
Netilmicin 8 16 32 8 16 50.0 8 16 56.0 0.55
Meropenem 4 8 16 1 2 95.0 1 2 98.0 0.365
Azlocillin 64 128 64 65 62.5 64 64 84.2 0.015
a All samples were resistant to cefoxitin and cefpodoxime.
b Based on interpretive breakpoints as indicated in NCCLS document M100-S10 (M7) (20) S. susceptible; I, intermediate; R, resistant.
c Drug not indicated for treatment of P. aeruginosa infections, even with susceptibility (19).
d The difference in the susceptibility rates between the mucoid and nonmucoid groups was considered statistically significant.
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P. aeruginosa displaying the same resistance profile. In the
remaining six patients the subsequent isolates displayed higher
rates of antimicrobial resistance than the initial isolate.
Twelve patients were colonized with both mucoid and non-
mucoid isolates, which were compared by molecular typing.
Five patients presented mucoid and nonmucoid isolates
with distinct PFGE profiles, while seven patients harbored
indistinguishable isolates regardless of colonial morphol-
ogy. Among these seven patients, a change of the colonies
from nonmucoid to mucoid was observed in five patients,
and a change from mucoid to nonmucoid was observed in
two patients.
DISCUSSION
Analysis of the antimicrobial susceptibilities of isolates
showed that high rates of resistance to antimicrobial agents
indicated for the treatment of CF P. aeruginosa occurred, es-
pecially among mucoid isolates. However, the carbapenens
(imipenem and meropenem) remained very active against both
mucoid and nonmucoid isolates, with susceptibility rates of
90%. The P. aeruginosa strains evaluated in the present study
showed higher rates of susceptibility than P. aeruginosa strains
from CF patients evaluated in other studies (6, 27). We also
observed that mucoid isolates showed a tendency for higher
rates of resistance (P  0.001) than nonmucoid isolates to
several antimicrobial agents, including cefperazone, cefepime,
aztreonam, sparfloxacin, and ciprofloxacin (23).
Despite the great number of studies on the epidemiology of
P. aeruginosa infection in CF (1, 4, 5, 12, 14, 15, 16, 22, 26, 30),
no data have been published on the colonization or infection of
Brazilian CF patients with P. aeruginosa. We evaluated 97
isolates of P. aeruginosa from 43 CF patients, and we found 39
distinct PFGE patterns among isolates from 41 patients that
were not epidemiologically related. Only two nonrelated pa-
tients shared indistinguishable isolates. On the other hand,
we also found that 12 out of 13 isolates obtained from two
CF siblings (closely related patients) displayed the same
PFGE pattern. Similarly to other reports, these results sug-
gest that cross-infection of P. aeruginosa among CF patients
would occur more frequently when contact was more intense
(12).
Our study also documented the permanence of a single
genotype in a patient over time. We observed the presence of
the original strain isolated two to six times over 22 months in
18 patients. Ten of these 18 patients harbored a single geno-
type with a conserved macrorestriction pattern over time
(3 to 17 months). These results suggest that even during
FIG. 1. PFGE of 20 clinical isolates of P. aeruginosa from 20 different patients. Lane , lambda ladder (48.5 kb). Lanes 1 to 20, clinical isolates
of P. aeruginosa from 20 different patients.
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periods of antibiotic therapy, the original strain is not erad-
icated from these patients. Another interesting finding was
the presence of variations of the same genotype (subtypes)
of P. aeruginosa in two single patients, as published by other
authors (30).
The remaining six patients carried two totally different ge-
notypes, and usually each one of these strains was isolated
from different specimens and on different days (Table 2). A
mixed colonization of different clones of P. aeruginosa can
explain this finding. The clone that predominates would vary
over time, with one clone predominating in one period and
another clone predominating in another period. This event
suggests that P. aeruginosa infection and colonization of the CF
patient’s lung is a very dynamic process, as proposed by Ren-
ders et al. (25).
The most relevant result of our study was the finding of
several different genotypes in five patients of group 2 (21.7%).
These patients had two to four distinct strains (distinct major
PFGE patterns) isolated during the follow-up period (2 to 13
months). All PFGE patterns were detected only once in these
subgroups of patients. In contrast to other studies (1, 5, 12,
14, 15, 16, 26, 30), these results suggest that the coloniz-
ing strain may occasionally be replaced. Boukadida et al.
(4) also found different strains in the same patient and
observed that the emergence of distinct strains in the same
CF patient was often associated with periods of antibiotic
therapy.
Among the 97 clinical isolates of P. aeruginosa included in
our study, 40 presented the mucoid appearance, confirming
that this phenotypic alteration is also very common among
P. aeruginosa strains from Brazilian CF patients (13). More-
over, it was possible to determine that mucoid and nonmucoid
isolates were indistinguishable by PFGE in 7 out of 12 patients
colonized with these colonial variants. This finding confirmed
the clonal relationship between mucoid and nonmucoid iso-
lates of P. aeruginosa from the same CF patient, as previously
demonstrated (17, 26, 32).
In conclusion, the results of this study indicate that in spite
of the fact that the CF patients had received courses of anti-
biotic therapy periodically, nonmucoid P. aeruginosa strains
isolated from their lung showed relatively low rates of antimi-
crobial resistance. Among unrelated patients, we detected only
one pair of patients sharing isolates with identical PFGE pat-
terns, and we concluded that cross-infection is not common in
our population. Our results also indicate that CF patients re-
main colonized by more than one strain of P. aeruginosa for
long periods of time. In addition, the finding of several isolates
with distinct genotypes in the same patient suggests that the
colonizing strain may occasionally be replaced.
FIG. 2. Genotypes of P. aeruginosa isolates from six CF patients. Lanes 1, 2, and 3, patient 9; lanes 4, 5, and 6, patient 10; lanes 7, 8, and 9,
patient 17; lanes 10, 11, 12, and 13, patient 6; lanes 14, 15, and 16, patient 5; lanes 17, 18, 19, and 20, patient 14; lane , lambda ladder (48.5 kb).
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2 3 9 5a 2 1 C1, C2
5b 1 C
3 3 10 6 1 C3
7 1 A
8 1 A
4 3 8 9 3 8 A
5 3 12 10 1 A
11 1 A
12 1 A
6 4 14 13 2 14 B
14 2 2 A, A2
7 3 9 15 3 9 A1
8 3 11 16 1 B2
17 2 3 A, D3
9 3 12 18 1 A
19 2 2 A
10 3 9 20 2 9 A1, E
21 1 A
11 6 17 22 6 17 D1, D2
12 7 19 22 6 19 D, D3, F, G
23 1 G
13 2 3 24 2 3 H
14 4 16 25 4 16 I, F1
15 2 13 35 1 J
36 1 K
16 5 11 26 1 A
27 4 11 A
17 3 3 28 3 3 L, M, M1
18 2 4 29 2 4 A
19 3 3 30 3 3 A1, A, B
20 3 11 31a 2 7 N
31b 1 O
21 2 0 32 2 A1, A3
22 2 2 33 1 M2
37 1 P
23 4 3 34 4 3 A4, Q
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